65 Vaccine CRO and CDMO vendors

What does it take to develop and manufacture a Vaccine drug?

A vaccine is unusual among modalities because the thing you are selling is an immune response, not a molecule that acts directly on a target. That one fact reshapes the whole development program. Your readout is not a binding constant or a tumor-growth curve, it is whether the construct raises the right kind of immunity (neutralizing antibodies, a balanced T-cell response, durability over time) and whether it does so without unacceptable reactogenicity. So discovery here is antigen design and selection: choosing the immunogen (a surface protein, a stabilized prefusion conformation, a polysaccharide, an attenuated organism, or an mRNA-encoded antigen), then proving it in immunogenicity and challenge studies in animal models before anything goes near a person.

The other complication is that vaccine is not one platform, it is at least five, and the CRO and CDMO work splits hard along those lines. An mRNA vaccine is an in-vitro-transcription program with LNP encapsulation, so it pulls in RNA drug substance, lipid formulation, and fill-finish. A viral-vector vaccine (adenoviral, for example) is a cell-culture and downstream-purification problem closer to gene therapy. A protein-subunit vaccine is recombinant-protein expression plus, almost always, an adjuvant. A conjugate vaccine chemically links a polysaccharide to a carrier protein. A live-attenuated or inactivated vaccine is classic biologics fermentation or egg or cell-based culture. The capabilities that matter, and the vendors who have them, are different in each case.

This is exactly where a specialist vaccine CDMO pulls away from a generalist. The wet-lab steps (express a protein, run a bioreactor, fill a vial) look generic on a capability slide, but vaccines carry their own baggage: adjuvant formulation and characterization (aluminum salts, oil-in-water emulsions like squalene-based systems, TLR-agonist adjuvants), a potency assay that actually predicts protection rather than just measuring how much antigen is present, immunogenicity assays validated to read the response (ELISA, neutralization titers, ELISpot, intracellular cytokine staining by flow), and cold-chain or lyophilization to keep a fragile biologic stable. A generalist CDMO can make the drug substance; a vaccine-experienced one knows how to prove it works and how to keep it alive in a vial. Match the vendor to your platform before anything else, because a brilliant mRNA shop is irrelevant to a conjugate program, and vice versa.

How do you choose a CRO or CDMO for Vaccine?

Vaccine is a platform-first decision, more so than most modalities, because the safety, analytical, and manufacturing baggage changes completely between mRNA, viral vector, protein subunit, conjugate, and live-attenuated. Score two or three vendors against the same written scope (platform, antigen, scale, quality grade, whether adjuvant and fill-finish are included) so you are comparing the same work and not three differently shaped quotes. The checklist below is what actually predicts a usable program.

• Relevant platform and track record: real, completed work in your specific platform (mRNA/LNP, adenoviral or other viral vector, recombinant protein subunit, polysaccharide conjugate, live-attenuated or inactivated), not a generic vaccine claim. Ask for comparable programs the team has taken from construct to clinical material, and which antigens or vectors they have actually handled.
• GxP and analytical capability for vaccines: GMP status (21 CFR Part 211, EU GMP) for clinical supply and GLP for the safety package, plus the vaccine-specific analytics that decide the program. That means a validated potency assay tied to the mechanism of protection, immunogenicity readouts (neutralizing-antibody titers, ELISA, ELISpot, intracellular cytokine staining), and identity, purity, and stability methods, qualified or validated rather than improvised per batch.
• Adjuvant and formulation experience: if your subunit or inactivated program needs an adjuvant, confirm the vendor can formulate and characterize it (aluminum salts, oil-in-water emulsion, liposomal or TLR-agonist systems) and has done so before. For mRNA, confirm LNP encapsulation scope; for lyophilized or cold-chain products, confirm the lyo cycle development and stability program.
• Capacity and scale: the slot availability and the scale you can grow into, from milligram or small-batch tox material through clinical supply and, if relevant, the very large volumes vaccines often need at commercial. A site built for a few liters is the wrong choice for a population-scale program, and an industrial vaccine plant is over-built for a small therapeutic-vaccine trial. Ask where the critical path sits (often template, seed-bank, raw-material lead times, or assay readiness rather than the core reaction).
• Regulatory experience: which agencies the vendor has filed and been inspected by (FDA CBER, EMA, WHO prequalification for global-health programs), and whether they understand the vaccine-specific expectations, including the comparability and lot-consistency work regulators look for. A clean inspection history in your target market is worth more than a low per-unit price.
• IP and confidentiality: who owns process improvements and any platform-derived inventions, how your antigen sequence, vector, or strain is protected, freedom-to-operate on licensed adjuvant or delivery technology (LNP lipids and certain adjuvants are heavily patented), and clean tech-transfer terms if you move the process to another site later.